Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A. Ailawadhi S, et al. Among authors: mulligan g. Leuk Lymphoma. 2012 Jun;53(6):1174-82. doi: 10.3109/10428194.2011.637212. Epub 2011 Dec 6. Leuk Lymphoma. 2012. PMID: 22054286
A gene expression signature for high-risk multiple myeloma.
Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P. Kuiper R, et al. Among authors: mulligan g. Leukemia. 2012 Nov;26(11):2406-13. doi: 10.1038/leu.2012.127. Epub 2012 May 8. Leukemia. 2012. PMID: 22722715
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B. Zhan F, et al. Among authors: mulligan g. Blood. 2008 Jan 15;111(2):968-9. doi: 10.1182/blood-2007-10-119321. Blood. 2008. PMID: 18182586 Free PMC article. No abstract available.
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.
van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC, van der Holt B, Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS, Sonneveld P. van Duin M, et al. Among authors: mulligan g. Haematologica. 2011 Nov;96(11):1662-9. doi: 10.3324/haematol.2010.037978. Epub 2011 Jul 26. Haematologica. 2011. PMID: 21791470 Free PMC article. Clinical Trial.
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M. Mulligan G, et al. Blood. 2014 Jan 30;123(5):632-9. doi: 10.1182/blood-2013-05-504340. Epub 2013 Dec 11. Blood. 2014. PMID: 24335104 Free PMC article. Clinical Trial.
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD Jr, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC. Mulligan G, et al. Blood. 2007 Apr 15;109(8):3177-88. doi: 10.1182/blood-2006-09-044974. Epub 2006 Dec 21. Blood. 2007. PMID: 17185464 Free article. Clinical Trial.
RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.
Hofman IJF, van Duin M, De Bruyne E, Fancello L, Mulligan G, Geerdens E, Garelli E, Mancini C, Lemmens H, Delforge M, Vandenberghe P, Wlodarska I, Aspesi A, Michaux L, Vanderkerken K, Sonneveld P, De Keersmaecker K. Hofman IJF, et al. Among authors: mulligan g. Leukemia. 2017 Aug;31(8):1706-1714. doi: 10.1038/leu.2016.370. Epub 2016 Dec 2. Leukemia. 2017. PMID: 27909306 Free PMC article.
Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.
Gerecitano J, Gounder S, Teruya-Feldstein J, Arcila M, Ogilvie S, Gonzalez C, Lin D, Zheng J, Zhang Z, McDonald A, Mulligan G, O'Connor OA. Gerecitano J, et al. Among authors: mulligan g. Br J Haematol. 2012 Jul;158(2):290-292. doi: 10.1111/j.1365-2141.2012.09137.x. Epub 2012 Apr 26. Br J Haematol. 2012. PMID: 22533368 Free article. Clinical Trial. No abstract available.
89 results